Session » (1100–1123) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1100

A Comparison of Characteristics of Patients with Crystalline and Septic Arthritis Confirmed by Synovial Fluid Analysis: Towards the Development of a Diagnostic Rule

9:00AM-11:00AM: Abstract Number: 1112

AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses

9:00AM-11:00AM: Abstract Number: 1121

Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials

9:00AM-11:00AM: Abstract Number: 1113

Comparing a Capillary Urate Point-Of-Care Device to Standard Laboratory-based Serum Urate Test for Dose Titration in Gout Patients

9:00AM-11:00AM: Abstract Number: 1104

Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial

9:00AM-11:00AM: Abstract Number: 1105

Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout Patients

9:00AM-11:00AM: Abstract Number: 1115

EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Crystal-induced Arthropathies in Clinical Practice

9:00AM-11:00AM: Abstract Number: 1103

Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy

9:00AM-11:00AM: Abstract Number: 1102

Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)

9:00AM-11:00AM: Abstract Number: 1109

Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis

9:00AM-11:00AM: Abstract Number: 1108

Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout

9:00AM-11:00AM: Abstract Number: 1106

Monosodium Urate and Calcium Pyrophosphate Crystal-induced Inflammation Relies on Cell Volume Regulation and LRRC8/VRAC Channel Activation

9:00AM-11:00AM: Abstract Number: 1110

Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout

9:00AM-11:00AM: Abstract Number: 1107

Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapy

9:00AM-11:00AM: Abstract Number: 1119

Preliminary Descriptive Analysis of the RADIAL Cohort Study About the Prevalence and the Clinical Characteristics of Patients with CPPD in Daily Clinical Practice

9:00AM-11:00AM: Abstract Number: 1123

Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016

9:00AM-11:00AM: Abstract Number: 1114

Role of Dual-energy Computed Tomography (DECT) in Detection of Carotid Artery Monosodium Urate Deposition in Patients with Gout

9:00AM-11:00AM: Abstract Number: 1117

Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis

9:00AM-11:00AM: Abstract Number: 1101

Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia

9:00AM-11:00AM: Abstract Number: 1120

Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients

9:00AM-11:00AM: Abstract Number: 1116

The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System

9:00AM-11:00AM: Abstract Number: 1118

The Nomenclature of Calcium Pyrophosphate Deposition (CPPD) Disease – Results of a Systematic Literature Review for the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) CPPD Nomenclature Project

9:00AM-11:00AM: Abstract Number: 1122

The Tophus Impact Questionnaire (TIQ-20): Responsiveness to Change During Urate-Lowering Therapy

9:00AM-11:00AM: Abstract Number: 1111

Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].